Alzinova - Setting the Conditions for Success
2022-06-21 10:30:00
Redeye revisits the Alzinova equity story following the company’s continued pipeline progress and recent rights issue. We continue to see the lead candidate, ALZ-101, as a candidate that stands out from other Alzheimer’s treatments. We argue that Alzinova offers an exciting investment opportunity and see an attractive entry point for the long-term oriented investor.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/